ARCpoint

ARCpoint AAQS

The The AAQS of ARCpoint (ARC.V) as of Oct 24, 2026 is 3. In the previous year, The AAQS was 3.00 — a change of 0.00% (lower).

AAQS

3

YoY

0.00%

Last updated:

ARCpoint has a current AAQS of 3.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock ARCpoint in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The ARCpoint AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2021
3.00 USD
Jan 1, 2022
3.00 USD
Jan 1, 2023
3.00 USD
Jan 1, 2024
3.00 USD
Jan 1, 2025
3.00 USD
The ARCpoint AAQS history
YEARAAQSYoY
30.00%
30.00%
30.00%
30.00%
3—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ARCpoint Stock analysis

What does ARCpoint do? ARCpoint, Inc. generates revenue through its franchise system, which includes drug testing, alcohol screening, DNA, and clinical lab testing services. The ARCpoint Franchise segment sells franchises to individuals across the United States, providing marketing, technology, and training support. The AFG Services segment offers clinical testing, software services, and diagnostic testing kits to franchisees and other business-to-business customers. The Other segment operates corporate-owned labs that serve businesses, physicians, and customers directly. Revenue streams include franchise fees, sales of diagnostic kits, and corporate lab services. ARCpoint Franchise segment revenue comes from franchise sales and ongoing support services. AFG Services segment revenue is derived from clinical testing, software services, and direct sales of diagnostic kits to business customers. Corporate-owned labs in the Other segment provide clinical and diagnostic services to businesses, physicians, and end customers, contributing to overall revenue. The company's business model relies on a mix of franchise sales, service offerings, and direct B2B transactions. The company's primary customers are individuals purchasing franchises, businesses requiring clinical testing, and physicians seeking diagnostic services. Franchisees benefit from ARCpoint's marketing, technology, and training support. AFG Services targets businesses needing diagnostic kits and software solutions. Corporate-owned labs serve businesses, physicians, and end customers with comprehensive testing solutions. Revenue is generated through multiple channels within the company's segmented structure. ARCpoint is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ARCpoint stock

The AAQS of ARCpoint is 3 in 2025.

On Eulerpool you can find the complete historical development of The AAQS ARCpoint since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — ARCpoint

All Key Metrics — ARCpoint